A new study from Springer Nature, part of Macmillan Publishers Limited, reveals CBD (cannabidiol) can be used as a treatment in curbing cocaine and alcohol relapse in lab animals. The Neuropsychopharmacology study from Nature Journal serves as further proof that cannabinoids do have therapeutic value.
Much of the cannabis-focused scientific community and business owners are aware of these benefits. However, this study is a welcomed addition to the mounting evidence in favor of treating patients with CBD- as well as calling cannabis medicine.
While the outcome of this study is exciting, there are hundreds of other animal/preclinical studies that have demonstrated the potential of CBD for human health. Until the government allows comprehensive double-blind randomized placebo-controlled studies on human populations these studies will continue to pile up without any action or validation.
This is a step in the right direction when a study like this comes out since it corroborates the decade of anecdotal evidence that has been seen firsthand. Some of the top reasons cannabis users go to dispensaries are to reduce their use of pharmaceuticals, street drugs, alcohol, and cigarettes.
It is one of the fastest-growing markets in the cannabis industry because anyone can use CBD without the psychoactive effects of products with THC. Facts from the published study:
- CBD attenuated context-induced and stress-induced drug seeking without tolerance, sedative effects, or interference with normal motivated behavior.
- Following treatment termination, reinstatement remained attenuated for up to ≈5 months.
- CBD also reduced experimental anxiety and prevented the development of high impulsivity in rats with an alcohol dependence history.
Customers and patients can shop online for vaping the oil, topical muscle freeze, and their CBD-releasing transdermal CBD gel pen – the same method of delivery used by researchers for this new study.
Unlike products with THC, CBD can be shipped across America because CBD is found in industrial hemp. Industrial hemp is legal across the United States and most of the world so that provides hemp-infused product manufacturers more freedom than cannabis product manufacturers.
Being able to sell products online and ship them nationwide is a game changer, and it allows for plant-based remedies to quickly and easily reach those who need them most. And there is also breaking new ground in the scientific community as they were the first to release products with lesser-known compounds of the plant including; THCa, CBN, and CBC.
This new era of cannabis research is great for patients and businesses. Savvy small business owners know that by providing consumers with the option of CBD products, their cannabis business can increase sales. In addition to providing a higher level of customer satisfaction, CBD products hold a higher sales value and will give a larger return as opposed to high-THC products.
In the past decade, the medical community has seen more cannabinoid-related studies than at any other time in history. As the industry and medical communities continue to establish cannabis as medicine, it’s only a matter of time before governments around the world remove cannabis from its list of banned substances without medical benefits.
The political implications of the study aren’t lost on the authors. They wrote, “the findings also inform the ongoing medical marijuana debate concerning medical benefits of non-psychoactive cannabinoids and their promise for development and use as therapeutics.” The issue of marijuana legalization and the medical application of CBD are separate.
Let us know what you think.
Responses